Q2 EPS Forecast for Soleno Therapeutics Boosted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - HC Wainwright lifted their Q2 2026 earnings estimates for Soleno Therapeutics in a research report issued on Friday, May 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.17 per share for the quarter, up from their previous forecast of $0.16. HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics' Q3 2026 earnings at $0.41 EPS and FY2026 earnings at $1.24 EPS.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.19.

SLNO has been the topic of a number of other reports. Cantor Fitzgerald increased their target price on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Laidlaw increased their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Lifesci Capital upgraded Soleno Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 4th. Stifel Nicolaus raised their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. Finally, Piper Sandler upped their price objective on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $106.78.

Soleno Therapeutics Price Performance

Shares of NASDAQ:SLNO traded down $2.11 during midday trading on Monday, reaching $73.51. The company had a trading volume of 111,453 shares, compared to its average volume of 981,438. The stock's fifty day moving average price is $71.04 and its 200-day moving average price is $56.23. The stock has a market capitalization of $3.70 billion, a P/E ratio of -22.14 and a beta of -2.67. Soleno Therapeutics has a one year low of $36.93 and a one year high of $80.99.

Insider Transactions at Soleno Therapeutics

In related news, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the transaction, the chief executive officer now owns 577,076 shares in the company, valued at $39,021,879.12. This trade represents a 54.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Patricia C. Hirano sold 128,653 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the sale, the insider now owns 55,789 shares in the company, valued at $3,811,504.48. This represents a 69.75% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 942,672 shares of company stock valued at $64,058,781. Company insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SLNO. Barclays PLC increased its position in Soleno Therapeutics by 149.3% in the 3rd quarter. Barclays PLC now owns 52,545 shares of the company's stock worth $2,652,000 after purchasing an additional 31,467 shares during the last quarter. JPMorgan Chase & Co. grew its position in Soleno Therapeutics by 35.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 13,915 shares of the company's stock worth $703,000 after purchasing an additional 3,666 shares during the last quarter. Avior Wealth Management LLC bought a new stake in shares of Soleno Therapeutics during the fourth quarter valued at approximately $89,000. Moody Aldrich Partners LLC acquired a new position in shares of Soleno Therapeutics in the 4th quarter worth approximately $1,331,000. Finally, Rhumbline Advisers grew its position in Soleno Therapeutics by 11.8% during the 4th quarter. Rhumbline Advisers now owns 34,395 shares of the company's stock worth $1,546,000 after acquiring an additional 3,624 shares during the last quarter. Institutional investors and hedge funds own 97.42% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.